trending Market Intelligence /marketintelligence/en/news-insights/trending/qcig4rcdys06xtte7_qi4q2 content esgSubNav
In This List

TapImmune raises $3.1M via stock purchase agreement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TapImmune raises $3.1M via stock purchase agreement

TapImmune Inc. raised gross proceeds of about $3.1 million under a stock purchase agreement.

Under the agreement, an existing accredited investor bought 1,300,000 common shares at $2.40 each in a private placement.

Additionally, TapImmune raised gross proceeds of about $2 million under a warrant exercise agreement.

Under the agreement, certain existing institutional investors bought 782,506 shares at a reduced exercised price, and for cash immediately.

Jacksonville, Fla.-based TapImmune develops immunotherapeutics and vaccines for cancer and metastatic disease.